Clinical trial
Effect of Roflumilast on Lung Function in Chronic Obstructive Pulmonary Disease…
NCT00313209 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00313209 |
|---|---|
| Title | Effect of Roflumilast on Lung Function in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Salmeterol: The EOS Study (BY217/M2-127) |
| Official title | Effect of Roflumilast in COPD Patients Treated With Salmeterol. A 24-week, Double-blind Study With 500 μg Roflumilast Once Daily Versus Placebo. The EOS Study |
| Acronym | EOS |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Chronic Obstructive Pulmonary Disease (COPD) |
| Intervention type | Drug |
| Interventions | Roflumilast, Placebo |
| Enrollment | 933 |
| Start date | Apr 1, 2006 |
| Primary completion | Jul 1, 2007 |
| Completion | Feb 1, 2008 |
| First posted | Apr 12, 2006 |
| Last update posted | Dec 14, 2016 |
| Countries | Austria, Belgium, Canada, France, Germany, Italy, Netherlands, South Africa, Spain, United Kingdom |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: